Literature DB >> 23797814

Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.

Zhizhen Dong, Min Yao, Li Wang, Xiaodi Yan, Xing Gu, Yun Shi, Ninghua Yao, Liwei Qiu, Wei Wu, Dengfu Yao.   

Abstract

Abnormal signaling of insulin-like growth factor I receptor (IGF-IR) is associated with hepatocellular carcinoma, but the underlying molecular mechanisms remain largely unknown. The objective of this study was to investigate IGF-IR's role as a signaling molecule, its pathological alteration in hepatoma tissues, and its effect on hepatoma cell proliferation when inhibited. As measured by immunohistochemical analysis, the incidence of hepatic IGF-IR expression in cancerous tissue was 80.0 % (24 of 30), which was significantly higher (P < 0.05) than 43.3 % (13 of 30) occurrence in the surrounding tissue and the nondetectable (0 of 30) frequency in the distal cancerous tissue. Hepatoma IGF-IR expression was correlated to the differentiation degree and not to the number or size of tumors, HBV infection, and AFP level. The in vitro IGF-IR expression in hepatoma cells was down-regulated significantly by picropodophyllin, a specific kinase inhibitor, in a time- and dose-dependent manner. Cell proliferation was inhibited through typical mechanisms of promoting apoptosis and cell cycle arrest (G2/M phase). Up-regulation of IGF-IR in hepatocarcinogenesis suggests that the down-regulation of IGF-IR expression could be a specific molecular target for hepatoma cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797814     DOI: 10.1007/s13277-013-0912-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  Molecular signatures and prognosis of hepatocellular carcinoma.

Authors:  Y Hoshida
Journal:  Minerva Gastroenterol Dietol       Date:  2011-09

Review 2.  Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis.

Authors:  Joseph E Maakaron; Maria Domenica Cappellini; Giovanna Graziadei; Jad Bou Ayache; Ali T Taher
Journal:  Ann Hepatol       Date:  2013 Jan-Feb       Impact factor: 2.400

Review 3.  New progress of non-surgical treatments for hepatocellular carcinoma.

Authors:  Ji-Wen Cheng; Yi Lv
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

4.  Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma.

Authors:  Chia-Jui Weng; Yi-Hsien Hsieh; Chiung-Man Tsai; Yin-Hung Chu; Kwo-Chang Ueng; Yu-Fan Liu; Yuan-Hung Yeh; Shih-Chi Su; Yi-Chen Chen; Mu-Kuan Chen; Shun-Fa Yang
Journal:  Ann Surg Oncol       Date:  2010-01-30       Impact factor: 5.344

Review 5.  Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

6.  Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients.

Authors:  H M El Tayebi; W Salah; I H El Sayed; E M Salam; A R N Zekri; N Zayed; E S Salem; G Esmat; A I Abdelaziz
Journal:  Biomarkers       Date:  2011-04-20       Impact factor: 2.658

Review 7.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

8.  Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis.

Authors:  Tsuneyuki Ubagai; Takane Kikuchi; Toshio Fukusato; Yasuo Ono
Journal:  Toxicol In Vitro       Date:  2009-12-29       Impact factor: 3.500

9.  Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.

Authors:  Craig I Campbell; Roger A Moorehead
Journal:  BMC Cancer       Date:  2011-11-09       Impact factor: 4.430

10.  Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.

Authors:  Wei Cheng; Chia-Jen Tseng; Tom T C Lin; I Cheng; Hung-Wei Pan; Hey-Chi Hsu; Yu-May Lee
Journal:  Carcinogenesis       Date:  2008-04-15       Impact factor: 4.944

View more
  5 in total

Review 1.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

2.  The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.

Authors:  Claudia Pivonello; Mariarosaria Negri; Maria Cristina De Martino; Maria Napolitano; Cristina de Angelis; Donatella Paola Provvisiero; Gaia Cuomo; Renata Simona Auriemma; Chiara Simeoli; Francesco Izzo; Annamaria Colao; Leo J Hofland; Rosario Pivonello
Journal:  Oncotarget       Date:  2016-03-01

Review 3.  Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Authors:  Agnieszka Adamek; Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

4.  Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells.

Authors:  Min Yao; Yin Cai; Zhi-Jun Wu; Ping Zhou; Wen-Li Sai; De-Feng Wang; Li Wang; Deng-Fu Yao
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

5.  PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines.

Authors:  Estefania Carrasco-Garcia; Isabel Martinez-Lacaci; Leticia Mayor-López; Elena Tristante; Mar Carballo-Santana; Pilar García-Morales; Maria Paz Ventero Martin; Maria Fuentes-Baile; Álvaro Rodriguez-Lescure; Miguel Saceda
Journal:  Cells       Date:  2018-09-06       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.